Premium
Premium statistics

Industry-specific and extensively researched technical data (partially from exclusive partnerships).

A paid subscription is required for full access.

Leading global anti-viral products by market share 2017 and 2024

Top 5 global anti-viral products by market share in 2017 and 2024

by Matej Mikulic, last edited Jun 19, 2019
Leading global anti-viral products by market share 2017 and 2024 This statistic displays the top 5 global anti-viral products based on their market share worldwide in 2017, and a projection for 2024. Gilead Sciences' Genvoya is expected to accumulate around 8.5 percent of the global market in anti-viral revenues by 2024. In the last years, Gilead Sciences’ Harvoni accounted for the largest share by a single drug of the world’s market share of anti-virals. Harvoni or Ledipasvir is used in the treatment of hepatitis C. This product was first marketed in October 2014. Hepatitis C is an infectious disease that can scar the liver and lead to cirrhosis.
Show more

Top 5 global anti-viral products by market share in 2017 and 2024

20172024*
---
---
---
---
---
20172024*
---
---
---
---
---
Exclusive Premium statistic

You need a Premium Account for unlimited access.

  • Full access to 1.5m statistics

  • Incl. source references

  • Available to download in PNG, PDF, XLS format

Premium Account

only $49 / month *
*Duration: 12 months, billed annually, single license

Access to this and all other statistics on 80,000 topics from

$588 / Year

Exclusive Premium statistic

You need a Premium Account for unlimited access.

  • Full access to 1.5m statistics

  • Incl. source references

  • Available to download in PNG, PDF, XLS format

Premium Account

only $49 / month *
*Duration: 12 months, billed annually, single license

Access to this and all other statistics on 80,000 topics from

$588 / Year

Download Settings Share
Download started
Please be patient - this may take a moment
by Matej Mikulic, last edited Jun 19, 2019
This statistic displays the top 5 global anti-viral products based on their market share worldwide in 2017, and a projection for 2024. Gilead Sciences' Genvoya is expected to accumulate around 8.5 percent of the global market in anti-viral revenues by 2024. In the last years, Gilead Sciences’ Harvoni accounted for the largest share by a single drug of the world’s market share of anti-virals. Harvoni or Ledipasvir is used in the treatment of hepatitis C. This product was first marketed in October 2014. Hepatitis C is an infectious disease that can scar the liver and lead to cirrhosis.
Show more
Statista Accounts: Access All Statistics. Starting from $588 / Year
Basic Account
Get to know the platform

You only have access to basic statistics.
This statistic is not included in your account!

Premium Account
Your perfect start with Statista
  • Instant access to 1m statistics
  • Download in XLS, PDF & PNG format
  • Detailed references

$49 / Month *

Corporate Account
Full access

Corporate solution including all features.

* All products require an annual contract.
   Prices do not include sales tax.
Leading companies trust Statista:
paypalgoogleadobepgsamsungtelekom
Statista is a great source of knowledge, and pretty helpful to manage the daily work.
Christof Baron

Christof Baron
CEO, MindShare Germany

Statistics on "Pharmaceutical market in Italy"
  • Market overview
The most important statistics
  • Pharmacy figures
  • Pharmaceutical expenditure
  • Pharmaceutical consumption
  • Brand name and generic drugs
  • Nonprescription drugs
  • Health supplements
Discover Statista
Need help with using Statista for your research? Tutorials and first steps
Further Content: Statistics, Studies, and Topic Pages
Learn more about how Statista can support your business.
Do you have any questions about our business solutions?

We provide you with detailed information about our Corporate Account.